Brain Diseases (Brain Disorder)

Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
Also Known As:
Brain Disorder; Brain Disease; Brain Disorders; CNS Disorders, Intracranial; Central Nervous System Disorders, Intracranial; Central Nervous System Intracranial Disorders; Encephalon Diseases; Intracranial CNS Disorders; Pathology, Brain; CNS Disorder, Intracranial; Encephalon Disease; Intracranial CNS Disorder; Brain Pathology; Intracranial Central Nervous System Disorders
Networked: 2114 relevant articles (58 outcomes, 188 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
2. Schizophrenia (Dementia Praecox)
3. Anoxia (Hypoxia)
4. Neurodegenerative Diseases (Neurodegenerative Disease)
5. Ischemia


1. Sharma, Hari Shanker: 14 articles (10/2015 - 01/2007)
2. Sharma, Aruna: 12 articles (10/2015 - 01/2009)
3. Muresanu, Dafin F: 9 articles (10/2015 - 12/2007)
4. Minghetti, Luisa: 8 articles (10/2011 - 09/2004)
5. Boado, Ruben J: 8 articles (07/2011 - 09/2007)
6. Patnaik, Ranjana: 7 articles (10/2015 - 01/2009)
7. Sharma, Hari S: 7 articles (10/2015 - 01/2006)
8. Hui, Eric Ka-Wai: 7 articles (07/2011 - 02/2010)
9. Pardridge, William M: 7 articles (07/2011 - 02/2010)
10. Lu, Jeff Zhiqiang: 7 articles (07/2011 - 02/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Brain Diseases:
1. Biological Markers (Surrogate Marker)IBA
10/01/2009 - "Proteomics for brain disorders--the promise for biomarkers."
08/01/2015 - "Overall, task modulation of FCV may represent an important direction for future studies, not only to provide insight into normal brain functioning but also to reveal potential biomarkers of various brain disorders."
07/01/2015 - "Witnessed by recent studies, functional connectivity is a useful concept in extracting brain network features and finding biomarkers for brain disease diagnosis. "
02/01/2015 - "Summit outputs include the following action plans, aligned to the pressure points within the brain research-drug development value chain: Code of conduct dealing with conflict of interest issues, Prevention, early diagnosis, and treatment, Linking science and regulation, Patient involvement in trial design, definition of endpoints, etc., Novel trial design, Reproduction and confirmation of data, Update of intellectual property (IP) laws to facilitate repurposing and combination therapy (low priority), Large-scale, global patient registries, Editorials on nomenclature, biomarkers, and diagnostic tools, and Public awareness, with brain disease advocates to attend G8 meetings and World Economic Forum (WEF) Annual meetings in Davos, Switzerland. "
01/01/2015 - "We hope that as biomarkers of exposures and processes leading to brain damage in the most immature newborns become more readily available, those who apply a systems approach to the study of neuroscience can be persuaded to study the pathogenesis of brain disorders in the very preterm newborn."
2. Brain-Derived Neurotrophic Factor (BDNF)IBA
3. AntioxidantsIBA
4. polyphenolsIBA
5. Opioid Receptors (Opioid Receptor)IBA
6. Amyloid (Amyloid Fibrils)IBA
7. Glutamic Acid (Glutamate)FDA Link
8. PPAR gammaIBA
9. Protons (Proton)IBA
10. PeptidesIBA

Therapies and Procedures

1. Enzyme Replacement Therapy
2. Therapeutics
3. Institutionalization (Institutionalized Persons)
4. Transplantation (Transplant Recipients)
5. Immunotherapy